LON:BXP - Beximco Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 79.80
▼ -0.2 (-0.25%)

This chart shows the closing price for BXP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beximco Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BXP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BXP

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Beximco Pharmaceuticals in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 79.80.

This chart shows the closing price for BXP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Beximco Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/30/2018Northland SecuritiesReiterated RatingBuy
7/23/2018Northland SecuritiesReiterated RatingBuy
7/9/2018Northland SecuritiesBoost Price TargetBuyGBX 75 ➝ GBX 84
4/23/2018Northland SecuritiesReiterated RatingBuyGBX 75
4/3/2018Northland SecuritiesReiterated RatingBuyGBX 75
4/3/2018Northland SecuritiesInitiated CoverageBuy
2/19/2018Northland SecuritiesInitiated CoverageBuyGBX 75
1/30/2018Northland SecuritiesReiterated RatingCorporate
1/19/2018Northland SecuritiesReiterated RatingCorporate
12/1/2017Northland SecuritiesReiterated RatingCorporate
11/14/2017Northland SecuritiesReiterated RatingCorporate
11/7/2017Northland SecuritiesReiterated RatingCorporate
10/6/2017Northland SecuritiesReiterated RatingCorporate
(Data available from 8/9/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Beximco Pharmaceuticals logo
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
Read More

Today's Range

Now: GBX 79.80
Low: 75.10
High: 79.90

50 Day Range

MA: GBX 75.29
Low: 67.50
High: 82.50

52 Week Range

Now: GBX 79.80
Low: 65
High: 131

Volume

12,317 shs

Average Volume

25,882 shs

Market Capitalization

£356.00 million

P/E Ratio

725.45

Dividend Yield

3.67%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Beximco Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Beximco Pharmaceuticals in the last year:
View the latest analyst ratings for BXP.

What is the current price target for Beximco Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Beximco Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of £100,000 for Beximco Pharmaceuticals in the next year.
View the latest price targets for BXP.

What is the current consensus analyst rating for Beximco Pharmaceuticals?

Beximco Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BXP.

What other companies compete with Beximco Pharmaceuticals?

How do I contact Beximco Pharmaceuticals' investor relations team?

Beximco Pharmaceuticals' physical mailing address is 19 Dhanmondi R/A, Road No. 7, DHAKA, 1205, Bangladesh. The company's listed phone number is +880-2-58611001. The official website for Beximco Pharmaceuticals is www.beximco-pharma.com. Learn More about contacing Beximco Pharmaceuticals investor relations.